MBX Biosciences (MBX) Current Assets (2023 - 2026)

MBX Biosciences has reported Current Assets for 4 years, with the latest figure at $448.5 million in Q1 2026.

• Quarterly Current Assets rose 83.62% year-over-year to $448.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $448.5 million (up 83.62% YoY) and the FY2025 annual result came in at $381.5 million, up 42.75% from the prior year.
• Current Assets grew to $448.5 million in Q1 2026 per MBX's latest filing, from $381.5 million in the prior quarter.
• Over five years, Current Assets peaked at $448.5 million in Q1 2026 and troughed at $83.5 million in Q4 2023.
• A 4-year average of $291.6 million and a median of $274.2 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets soared 220.24% in 2024, then jumped 41.37% in 2025.
• Over 4 years, Current Assets stood at $83.5 million in 2023, then jumped by 220.24% to $267.3 million in 2024, then jumped by 42.75% to $381.5 million in 2025, then rose by 17.56% to $448.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $448.5 million, $381.5 million, and $397.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.